Core Insights - Tactile Systems Technology, Inc. reported strong financial results for Q4 and full year 2025, highlighting double-digit revenue growth and improved profitability metrics [3][4][9]. Financial Performance - Q4 2025 total revenue increased by $18.0 million, or 21%, reaching $103.6 million compared to $85.6 million in Q4 2024 [4][7]. - Full year 2025 total revenue rose by $36.5 million, or 12%, to $329.5 million from $293.0 million in 2024 [9][10]. - Q4 2025 gross profit increased by $16.6 million, or 26%, to $81.0 million, with a gross margin of 78% compared to 75% in Q4 2024 [5][7]. - Full year 2025 net income was $19.1 million, or $0.82 per diluted share, up from $17.0 million, or $0.70 per diluted share in 2024 [10][8]. Product Line Performance - In Q4 2025, sales and rentals of the lymphedema product line increased by $12.4 million, or 16%, while airway clearance product line sales surged by $5.6 million, or 66% [4][9]. - For the full year 2025, lymphedema product line sales rose by $19.0 million, or 7%, and airway clearance product line sales increased by $17.5 million, or 52% [9]. Cash Flow and Balance Sheet - Operating cash flow for 2025 was $42.8 million, compared to $40.7 million in 2024 [7]. - As of December 31, 2025, the company had $83.4 million in cash and no outstanding borrowings, down from $94.4 million in cash and $26.3 million in borrowings at the end of 2024 [11]. Strategic Developments - The company acquired LymphaTech, enhancing its lymphedema solutions portfolio and R&D capabilities with digital 3D scanning technology [7]. - Tactile Medical anticipates continued growth in its lymphedema business and deeper collaborations with DME partners in the respiratory sector as it enters 2026 [3]. 2026 Financial Outlook - The company expects total revenue for 2026 to be between $357 million and $365 million, representing an 8% to 11% year-over-year growth [12]. - Adjusted EBITDA for 2026 is projected to be in the range of $49 million to $51 million, compared to $44.8 million in 2025 [12].

Core Viewpoint - Beta Bionics, Inc. reported strong financial results for Q4 and full year 2025, indicating significant growth in the durable insulin pump market and providing guidance for 2026 [1][5][12]. Financial Highlights Fourth Quarter 2025 - Net sales reached $32.1 million, a 57% increase from $20.4 million in Q4 2024 [5][21]. - Durable Medical Equipment (DME) channel net sales were $22.3 million, up 24% from $18.0 million in Q4 2024 [5][21]. - Pharmacy Benefit Plan (PBP) channel net sales surged to $9.8 million, a 295% increase from $2.5 million in Q4 2024 [5][21]. - Gross margin improved to 59.0%, up 179 basis points from 57.2% in Q4 2024 [5][21]. - The installed customer base grew to 35,011 users, a 129% increase from 15,298 in Q4 2024 [5][21]. - New patient starts totaled 5,592, a 37% increase from 4,084 in Q4 2024 [5][26]. Full Year 2025 - Total net sales for the year were $100.3 million, a 54% increase from $65.1 million in 2024 [5][21]. - DME channel net sales for the year were $75.8 million, up 29% from $58.8 million in 2024 [5][21]. - PBP channel net sales reached $24.4 million, a 287% increase from $6.3 million in 2024 [5][21]. - Gross margin for the year was 55.4%, up 29 basis points from 55.1% in 2024 [5][21]. - New patient starts for the year totaled 19,713, a 52% increase from 12,994 in 2024 [5][26]. Strategic Highlights - The company completed its first-in-human Phase 2a feasibility trial for its bihormonal system in New Zealand [5][6]. - An additional Phase 2a feasibility trial is expected to be initiated in the first half of 2026 [5][6]. - The company aims to progress to Phase 2b following the completion of the Phase 2a trial, which is anticipated to be a pivotal trial [5][6]. 2026 Guidance - Estimated total revenue for 2026 is projected to be approximately $130 million to $135 million [12]. - Expected gross margin for 2026 is estimated to be between 55.5% and 57.5% [12]. - The company anticipates that 36% to 38% of new patient starts will be reimbursed through the PBP channel [12].

On February 17, 2026, Nine Ten Capital Management disclosed selling 342,907 shares of IRadimed (NASDAQ:IRMD), an estimated $29.42 million trade based on quarterly average pricing. What happened According to a Securities and Exchange Commission (SEC) filing dated February 17, 2026, Nine Ten Capital Management reduced its position in IRadimed by 342,907 shares during the fourth quarter. The estimated value of the shares sold is approximately $29.42 million, calculated using the average closing price for th ...

Core Insights - Medtronic reported adjusted earnings of $1.36 per share, surpassing expectations of $1.33 [1] Segment Performance - Neuroscience Portfolio revenue reached $2.558 billion, reflecting a 4.1% increase reported and 2.5% organic growth, with mid-single digit increases in Neuromodulation and Cranial & Spinal Technologies, while Specialty Therapies remained flat on an organic basis [2] - Medical Surgical Portfolio revenue was $2.173 billion, marking a 4.9% increase as reported and 2.7% organic growth, driven by low-single digit growth in Surgical & Endoscopy and high-single digit growth in Acute Care & Monitoring on an organic basis [2] - Diabetes business revenue amounted to $796 million, showing a significant increase of 14.8% reported and 8.3% organic growth [2] Financial Outlook - Medtronic reiterated its fiscal 2026 organic revenue growth target of approximately 5.5% and adjusted earnings per share guidance of $5.62 to $5.66, which includes a potential tariff impact of about $185 million [4] - Excluding the tariff impact, the guidance indicates an adjusted EPS growth of approximately 4.5% for fiscal 2026 [4] Strategic Initiatives - The company emphasized its commitment to investing in R&D to enhance its innovation pipeline and executed two key transactions in the quarter as part of its M&A and venture strategy [5] - Medtronic announced its decision to acquire CathWorks, a privately held medical device company in Israel, with the acquisition valued at up to $585 million, including potential undisclosed earn-out payments [6]

Core Insights - The NASDAQ 100 (NDX) showed resilience, recovering from a nearly 1% pre-market decline to trade in flat-to-positive territory by late afternoon, influenced by Federal Reserve comments and regulatory shifts [2][10] Federal Reserve Commentary - Federal Reserve Governor Michael Barr indicated a cautious approach to monetary policy, suggesting inflation is expected to decrease as the effects of recent tariffs are absorbed by the economy, and the risk of a persistent inflation spiral is manageable [3][10] Regulatory Environment - The White House Council of Economic Advisers (CEA) reported that federal regulatory burdens cost U.S. consumers over $237 billion, which supports President Trump's campaign to dismantle the Consumer Financial Protection Bureau (CFPB) [4][10] Geopolitical Developments - Iranian media reported a temporary closure of the Strait of Hormuz due to security drills, highlighting the region's potential to disrupt 20% of the world's oil supply [5][10] Digital Asset Innovations - Tether announced a partnership with Elemental Royalty Corp (ELE) to allow shareholders to receive dividends in tokenized gold (XAU₮), bridging traditional commodity markets with blockchain technology [6][10] Individual Equity Movements - Norwegian Cruise Line Holdings (NCLH) rose by 7.2% following a significant investment from Elliott Investment Management, while Masimo Corp (MASI) surged over 30% on news of a potential $10 billion acquisition by Danaher (DHR), contributing to positive market sentiment [7][10]

Core Insights - Medtronic has launched a direct-to-consumer "Go Beyond" campaign, resulting in a significant increase in website traffic, with visits rising from approximately 50,000 to 2.5 million [1] - The company is focusing on scaling its Symplicity platform for renal denervation, targeting the 18 million patients in the U.S. with uncontrolled hypertension [2] - Medtronic's management highlighted strong growth in various product areas, including cardiovascular and diabetes segments, while reiterating financial guidance for fiscal 2026 and expectations for high single-digit adjusted EPS growth in fiscal 2027 [4][5] Product and Market Developments - The cardiovascular portfolio revenue grew 11% year-over-year, with a notable 80% growth in cardiac ablation systems (CAS), driven by pulsed field ablation (PFA) [12] - The MiniMed diabetes business reported a 15% increase in revenue, with significant growth attributed to international markets and new product launches [16] - Medtronic is scaling its Symplicity Spyral and Altaviva platforms, with early traction observed in patient referrals and physician training [6] Financial Performance - Medtronic reported revenue of $9.0 billion for the quarter, reflecting an 8.7% increase, with adjusted gross margin at 64.9% [5][17] - Adjusted operating profit reached $2.2 billion, with an adjusted operating margin of 24.1%, exceeding expectations [18] - The company maintained its fiscal 2026 organic revenue growth guidance of approximately 5.5% and adjusted EPS guidance of $5.62 to $5.66 [19] Regulatory and Technological Advancements - The Hugo robotic-assisted surgery system received FDA clearance for urologic procedures, marking the beginning of its U.S. launch [7] - The Stealth Access Surgical System for spinal procedures was also cleared by the FDA, integrating AI-powered planning and robotics [10][11] - Medtronic's Touch Surgery digital ecosystem installations surpassed 1,000 globally, showcasing a 20% sequential growth [8]

Danaher Corporation has agreed to acquire Masimo in a cash deal worth $9.9bn in an effort to broaden its diagnostics business in the telehealth space. Under the deal, which is valued at a price per share of $180, Danaher said that Masimo will become a standalone business unit and brand within its diagnostics unit, operating autonomously while strengthening the life science conglomerate’s offering in acute care settings. Pending customary closing conditions, the transaction is expected to complete in H2 20 ...

Core Insights - Spineway reported a revenue of €12.4 million for the year 2025, reflecting a 4% increase compared to 2024 [4][5] - The gross margin improved to €8.6 million, representing 69.6% of revenue, an increase of 0.6 percentage points year on year [5] - The company experienced a stable operating loss of €2.1 million, consistent with the previous year [5][7] Financial Performance - Revenue for 2025 was €12,430,000, up from €11,950,000 in 2024 [2] - Cost of sales increased to €3,783,000, leading to a gross margin of €8,647,000 [2] - Net operating expenses rose by 5% to €10,780,000, in line with revenue growth [5] - The net loss improved to €2,238,000 from €3,859,000 in 2024 [7] Operational Highlights - The company launched its ESP disc prosthesis production line and continued regulatory investments despite facing delays in approvals and supply chain issues [4] - External financing was limited to €0.4 million in 2025, a significant decrease from €6.8 million in 2024 [8] - Cash position at the end of 2025 was €3.5 million, with net cash after financial debt at €2 million [8] Growth Potential - Consolidated revenue has nearly tripled since 2021, driven by synergies from acquisitions [9] - Continued investment in regulatory affairs, marketing, and R&D is expected to enhance Spineway's growth potential [9]

Core Insights - The company experienced its strongest growth in the Cardiovascular portfolio in 10 years, achieving an 11% increase, primarily due to the rapid adoption of Pulse Field Ablation (PFA) [1] - Cardiac Ablation Solutions (CAS) saw an 80% growth attributed to the successful launch of the Affera mapping and navigation system and Sphere-9 catheter [1] - The company is shifting from foundational market-building to active commercial scaling for the Symplicity Spyral hypertension treatment and Altaviva for incontinence [1] - Strategic positioning in the spine market is being enhanced by the Stealth AXiS platform, which integrates AI-powered planning and robotics into existing surgical workflows [1] - A 30-basis-point benefit from pricing helped to mitigate negative impacts from inflation, prior-year non-recurring items, and a 20-basis-point headwind from cost-efficiency programs [1] - The Diabetes business experienced accelerated growth in the U.S. following the launch of Simplera Sync and Instinct, supported by expanded pharmacy channel access for the 780G system [1]

The 1RF brain ablation system saw significant adoption momentum, with nearly half of all historical ablations occurring within the first fiscal quarter of 2026. The 1RF trigeminal nerve ablation system entered a limited commercial launch, demonstrating a competitive advantage by requiring only a single probe placement compared to traditional multiple-placement systems. Management accelerated the drug delivery program by approximately six months, with devices now expected to be available for investigat ...